THE Ministry of Health and Child Care (MoHCC) has deffered roll out of the HIV Dolutegravir (DTG) drug following indications that it causes complications in women of child bearing age and adolescent girls, which might lead to deformities in unborn babies born to HIV positive mothers taking the drug at the time of conception. HealthTimes Reporter Zimbabwe intended to scale up Dolutegravir as a first choice ARV to all people living with HIV in the country next year. The drug is currently being used to manage HIV in people who fail…
Read MoreDay: June 16, 2018
Zim Launches Prep Strategy…Program targets key populations
ZIMBABWE has launched Pre Exposure Prophylaxis (PrEP) strategy for 2018 up to 2020 which is aimed at scaling up uptake of the PrEP drug amongst key populations and those at high risk of contracting HIV. By Michael Gwarisa Launching the strategy document, Health and Child Care minister, Dr David Parirenyatwa said Zimbabwe still faced a huge HIV challenge as it is still recording incidence around 32 000 people every year hence the need to increase prevention mechanisms. “Now I am proud to emphasise that we have successfully managed to reduce…
Read More